The Unique Properties of Placental Mesenchymal Stromal Cells: A Novel Source of Therapy for Congenital and Acquired Spinal Cord Injury.
Cells
; 10(11)2021 10 22.
Article
in English
| MEDLINE | ID: covidwho-1502368
ABSTRACT
Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Placenta
/
Spinal Cord Injuries
/
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Female
/
Humans
/
Pregnancy
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Cells10112837
Similar
MEDLINE
...
LILACS
LIS